ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO954

Outcomes of COVID-19 in Peritoneal Dialysis: A Multi-Centre Observational Study

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Gutty, Bhamini, University Hospitals Birmingham NHS Foundation Trust, Birmingham, Birmingham, United Kingdom
  • Baharani, Jyoti B., University Hospitals Birmingham NHS Foundation Trust, Birmingham, Birmingham, United Kingdom
Background

Patients with end stage renal failure are not only at high risk of developing Coronavirus disease 2019 (COVID-19) but there are reports of disproportionately severe impact on dialysis patients, with reported short-term mortality of 20% or higher. The aim of this study was to assess the impact of COVID-19 in patients on peritoneal dialysis (PD).

Methods

We conducted a retrospective observational study across four hospitals in West Midlands in United Kingdom. We identified a total of 50 patients on PD, 18 years and over, with a positive SARS-COV-2 swab from 1st of January 2020 to 31st of December 2020. Data was analysed using IBM SPSS software. We looked at mortality (7 days, 28 days, 3 months), intensive therapy unit (ITU) admission, ventilation requirement, peritonitis and conversion to haemodialysis.

Results

The mean age was 63 years, with higher prevalence in men (66%). 54% were of white ethnicity (46% of Black, Asian and minority ethnic groups). 10 out of the 50 patients (20%) had died within 7 days, 17 (34%) had died within 28 days and 19 (38%) were not alive at 3 months. 3 patients (6%) required ITU admission. 4 patients (8%) received non-invasive ventilation, but none required mechanical ventilation. 4 patients (8%) were converted to haemodialysis. 8 patients (16%) had peritonitis.

Conclusion

We found a high risk of short-term mortality in our PD patients who acquired COVID-19 infection. However, more studies are required to establish any causal link between COVID-19 infection in PD patients and high short-term mortality.